Fifty 1 Labs logo

Fifty 1 Labs(OTC) FITY

Market Cap$145.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-100%
1 Year-92%
1 Month-33%
$0.00
+0.00%
+0.00Today
Fifty 1 Labs last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-07
Fifty 1 Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%USD 0.002026-09-30
1 month-33.33%USD 0.002026-09-04
3 month-77.78%USD 0.002026-07-09
Year to date-60%USD 0.002025-12-31
1 year-91.67%USD 0.002025-10-07
3 year-98.89%USD 0.022023-10-05
5 year-99.62%USD 0.052021-10-04
Since inception-100%USD 4.252005-08-02

Fifty 1 Labs Financials at a Glance

Market Cap

$145.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$47.00

Net Income (TTM)

-$245.91K

EPS (TTM)

-$0.00

P/E Ratio

-1.00

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$0.00

Volume

1,700,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

May 12, 2026

FITY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fifty 1 Labs

Fifty 1 Labs, Inc. is a Nevada-based holding company focused on biotechnology and telehealth, specializing in peptide science for musculoskeletal health and performance. The company aims to leverage AI-driven research to develop personalized peptide therapies through a telehealth platform.

Products and Services
  • Biotechnology solutions targeting musculoskeletal health
  • Telehealth platform for personalized peptide therapies
  • AI-driven research and development in functional medicine
Growth Outlook
  • Transitioning from automotive finance to biotechnology and telehealth
  • Increasing demand for personalized healthcare solutions
  • Potential market expansion in the life sciences sector
Financial Highlights
  • Recent quarterly revenue of 47, indicating initial sales growth
  • Trailing twelve months (TTM) revenue of 364, showing upward momentum
  • Operating expenses decreased from 37,834 to 8,218 in recent quarters
Fifty 1 Labs, Inc. is positioned at the intersection of healthcare innovation and technology. The shift from automotive finance to biotechnology reflects a strategic pivot aimed at capitalizing on the growing demand for personalized healthcare solutions. The company's focus on peptide science and telehealth services aligns with current trends in functional medicine, which emphasize individualized treatment plans. Recent financial data indicates a modest revenue growth trajectory, with a quarterly revenue of 47 and a TTM revenue of 364. This growth is complemented by a significant reduction in operating expenses, suggesting improved operational efficiency. The company’s commitment to leveraging AI in research and development further enhances its potential for future growth in the life sciences sector. Investors may find Fifty 1 Labs, Inc. an intriguing opportunity as it navigates the evolving landscape of healthcare technology and personalized medicine.
AI Generated • Sep 24, 2026

Industry

Consumer Finance

Sector

Financials

Employees

3

CEO

Pritpaul Singh Arora, PhD

Website

www.cafius.com

Headquarters

Melbourne, FL 32934, US

FITY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-358397.87%

Net Income Margin

-523204.26%

Return on Equity

72.68%

Return on Capital

N/A

Return on Assets

-3859.77%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$145.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

727.07M

Volume

1.70M

Avg. Volume

16.07M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$168.45K

EBITDA

-$168.45K

Operating Cash Flow

-$282.14K

Capital Expenditure

$0.00

Free Cash Flow

-$282.14K

Cash & ST Invst.

$4.80K

Total Debt

$168.29K

Fifty 1 Labs Performance Analysis

Fifty 1 Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 92,117411.7%
20242024-06-30USD 72-99.9%
20252025-06-30USD 647798.6%
20262026-06-30USD 47-92.7%
Fifty 1 Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Q42026-06-30-100.0%
Fifty 1 Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.00100.0%
20242024-06-30USD 0.00N/A
20252025-06-30USD -0.00N/A
20262026-06-30USD -0.00-81.8%
Fifty 1 Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$145.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$72.70K

N/A

Employees

2

N/A

Net Income

-$197.07K

-3021.7%

EBITDA

-$119.61K

-1794.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$4.80K

+159900.0%

Total Debt

$168.29K

-20.1%

Accounts Receivable

$0.00

N/A

Inventory

$1.57K

N/A

Long Term Debt

$168.29K

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-38.60%

N/A

Return on Invested Capital

26.86%

N/A

Free Cash Flow

-$49.61K

-175.6%

Operating Cash Flow

-$49.61K

-175.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TNBITanke Biosciences Corporation
$0.03+200.00%
SVLTSunvault Energy, Inc.
$0.01+0.00%
ATNPQAtlantis Technology Group
$0.00+0.00%
IHAIInnovative Holdings Alliance, Inc.
$0.06+4.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.29+5.33%
BKLCBny Mellon ETF Trust - Bny Mellon Us Large Cap Core Equity ETF
$49.57-0.33%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$18.69-6.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$149.83-5.71%

Questions About FITY

What is the current price of Fifty 1 Labs?

Fifty 1 Labs is trading at $0.00 per share.

What is the 52-week range for Fifty 1 Labs?

Over the past 52 weeks, Fifty 1 Labs has traded between $0.00 and $0.00.

How much debt does Fifty 1 Labs have?

As of the most recent reporting period, Fifty 1 Labs reported total debt of $168.29K.

How much cash does Fifty 1 Labs have on hand?

Fifty 1 Labs reported $4.80K in cash and cash equivalents in its most recent financial results.

What is Fifty 1 Labs’s dividend yield?

Fifty 1 Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services